Home » Stocks » MESO

Mesoblast Limited (MESO)

Stock Price: $10.70 USD -0.20 (-1.83%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.25B
Revenue (ttm) 32.16M
Net Income (ttm) -77.94M
Shares Out 116.62M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE 114.94
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $10.70
Previous Close $10.90
Change ($) -0.20
Change (%) -1.83%
Day's Open 11.00
Day's Range 10.50 - 11.40
Day's Volume 287,465
52-Week Range 3.12 - 21.28

More Stats

Market Cap 1.25B
Enterprise Value 1.22B
Earnings Date (est) Feb 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 116.62M
Float n/a
EPS (basic) -0.74
EPS (diluted) -0.74
FCF / Share -0.59
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.99M
Short Ratio 3.96
Short % of Float n/a
Beta 2.88
PE Ratio n/a
Forward PE 114.94
P/FCF Ratio n/a
PS Ratio 38.80
PB Ratio 2.40
Revenue 32.16M
Operating Income -75.41M
Net Income -77.94M
Free Cash Flow -58.46M
Net Cash 30.01M
Net Cash / Share 0.26
Gross Margin 21.29%
Operating Margin -234.50%
Profit Margin -242.40%
FCF Margin -181.80%
ROA -6.82%
ROE -15.13%
ROIC -170.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$16.87*
(57.66% upside)
Low
5.78
Current: $10.70
High
25.14
Target: 16.87
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20202019201820172016201520142013
Revenue32.1616.7217.342.4142.5519.7623.3929.30
Revenue Growth92.3%-3.57%618.95%-94.33%115.31%-15.52%-20.17%-
Gross Profit32.1616.7217.342.4142.5519.7623.3929.30
Operating Income-75.41-81.16-74.69-90.09-119-80.91-71.20-66.15
Net Income-77.94-89.80-35.29-76.82-4.13-96.24-75.53-62.12
Shares Outstanding499483428381366366--
Earnings Per Share-0.74-0.91-0.38-0.96-0.06-1.50-1.18-1.05
Operating Cash Flow-56.37-57.79-75.01-95.47-88.00-101-74.91-55.75
Capital Expenditures-2.10-0.28-0.20-0.31-0.72-2.20-1.71-1.27
Free Cash Flow-58.46-58.07-75.21-95.78-88.72-103-76.62-57.01
Cash & Equivalents12950.4337.7645.7680.94111185-
Total Debt99.3181.2959.40-----
Net Cash / Debt30.01-30.86-21.6345.7680.94111185-
Assets734652692656684782847-
Liabilities184171146139156314309-
Book Value549481546517528468539-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mesoblast Limited
Employees 102
CEO Silviu Itescu

Stock Information

Ticker Symbol MESO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MESO

Description

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrĂ¼nenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.